Publications by authors named "B Gulbis"
Article Synopsis
- Loop diuretics like furosemide and bumetanide are essential for managing fluid overload in patients with acute decompensated heart failure, but their effectiveness can vary.
- This study compared the urine output responses of patients treated with intravenous furosemide versus bumetanide within 48 hours of hospital admission, focusing on total urine output over the following 24 hours.
- Results indicated that while both medications produced similar overall urine output, bumetanide resulted in a significantly higher urine output per milligram compared to furosemide, suggesting that higher doses of furosemide may be necessary to achieve similar effects.
Purpose: The purpose of this study is to compare the incidence of contrast-induced nephropathy (CIN) following percutaneous coronary intervention (PCI) in patients on sodium-glucose cotransporter-2 (SGLT-2) inhibitors prior to the procedure with a matched cohort of patients not receiving sodium-glucose cotransporter-2 inhibitor therapy.
Methods: In this retrospective observational study, patients were eligible for inclusion if they underwent PCI at any of the included study centers within the study time period. Patients were assigned to either the SGLT-2 inhibitor group or control group depending on the documentation of receiving any SGLT-2 inhibitors within 24 h prior to PCI.
Background: While renin-angiotensin system (RAS) inhibitors have a longstanding history in blood pressure control, their suitability as first-line in-patient treatment may be limited due to prolonged half-life and kidney failure concerns.
Methods: Using a cohort design, we assessed the impact of RAS inhibitors, either alone or in combination with beta-blockers, on mortality, while exploring interactions, including those related to end-stage renal disease and serum creatinine levels. Eligible subjects were Acute Ischemic Stroke (AIS) patients aged 18 or older with specific subtypes who received in-patient antihypertensive treatment.
Article Synopsis
- Sickle cell disease (SCD) is a serious genetic illness affecting many people in Europe, especially those from minority groups who might not have a lot of health education or support.
- To help these patients have a say in research about their illness, special events were organized where they could share their ideas and needs.
- These workshops helped patients, caregivers, and doctors work together better, making it easier to gather important research questions and educate everyone involved about SCD.
After the initiation of veno-arterial extracorporeal membrane oxygenation (V-A ECMO) for hemodynamic support, patients often require vasopressor and inotropic medications to support their blood pressure and cardiac contractility. The vasoactive-inotropic score (VIS) is a standardized calculation of vasopressor and inotrope equivalence, which uses coefficients for each medication to calculate a total value. This study evaluated the association between the 30-day survival of patients receiving V-A ECMO support and the VIS calculated 24 h after ECMO cannulation (VIS24).
View Article and Find Full Text PDF